Data completeness
1/8 — Limited
NORISODRINE (isoproterenol sulfate) by AbbVie is beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORISODRINE (isoproterenol sulfate) is a beta-adrenergic agonist inhaled powder indicated for bronchospasm and respiratory conditions requiring sympathomimetic stimulation. It works by activating beta-adrenergic receptors with minimal alpha-adrenergic activity, rapidly dilating airways and improving breathing. This is a pre-launch, non-biologic small molecule product from AbbVie.
PRE_LAUNCH
Pre-launch lifecycle indicates significant commercial buildout ahead; expect expanded team hiring across sales, marketing, and medical affairs during launch preparation.
Mechanism of Action
beta-adrenergic agonist with very low affinity for alpha‑adrenergic receptors.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NORISODRINE is in pre-launch phase, indicating high activity in regulatory, manufacturing, and commercial readiness functions within AbbVie. Career opportunities will be strongest in launch infrastructure roles—brand management, sales training, medical education, and operational scaling—before and immediately following approval.
Brand ManagerProduct Manager
Worked on NORISODRINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.